Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Hold” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus rating of “Hold” from the eleven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.50.

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group downgraded shares of Astria Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $30.00 to $13.00 in a research note on Tuesday, October 14th. Wedbush set a $13.00 price objective on shares of Astria Therapeutics and gave the stock a “neutral” rating in a report on Wednesday, October 15th. JMP Securities reaffirmed a “market perform” rating on shares of Astria Therapeutics in a research report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Astria Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright lowered Astria Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 16th.

Astria Therapeutics Price Performance

ATXS stock opened at $12.58 on Friday. The stock has a market capitalization of $718.13 million, a price-to-earnings ratio of -5.88 and a beta of 0.01. The company has a 50-day moving average of $12.77 and a two-hundred day moving average of $10.01. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $13.29.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The company had revenue of $0.71 million during the quarter, compared to analyst estimates of $10.67 million. Equities analysts expect that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in Astria Therapeutics by 10,311.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 3,506 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,557 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Astria Therapeutics in the third quarter valued at about $98,000. AXQ Capital LP acquired a new position in Astria Therapeutics in the third quarter worth about $115,000. Finally, Bailard Inc. bought a new position in Astria Therapeutics during the second quarter worth about $142,000. 98.98% of the stock is owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.